Literature DB >> 33631190

Short-chain free-fatty acid G protein-coupled receptors in colon cancer.

Nader H Moniri1, Qadan Farah2.   

Abstract

The dietary role of macronutrients and their metabolites in cancer has been evident for many decades. Dietary ingestion of fat, carbohydrates, protein, and fiber, as well as probiotics that influence gut microbiota, have all been linked to gastrointestinal (GI) tract health and disease, particularly in the colon, where it has long been known that fat and fiber can regulate inflammation and carcinogenesis. Short-chained fatty acids (SCFA), including acetate, propionate, and butyrate, which are biosynthesized by microbiota-mediated metabolism of dietary fiber, have previously been shown to play important roles in colorectal health, including decreasing inflammation and oxidative stress. Since the 1980s, a growing number of studies have also demonstrated a link between SCFA and colon epithelial cell carcinogenesis and prevention of colorectal cancers (CRC). While the effects of SCFA have historically been associated with their intracellular metabolism and function, the discovery of a family of G protein-coupled free-fatty acid receptors in the early 2000s suggests that many effects of SCFA are cell-surface receptor mediated. Indeed, the SCFA GPCRs FFA2 (previously termed GPR43), FFA3 (previously termed GPR41), and GPR109A are now well established to be expressed within the GI tract, where they modulate a variety of functions in response to luminal SCFA. While the role of SCFA in cancers, including CRC, has been reviewed in detail elsewhere, the goal of this report is to provide a review on the current body of evidence in regard to the effects of SCFA on FFA2, FFA3, and GPR109A in colon cancers.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colon cancer; FFA2 (GPR43); FFA3 (GPR41); Fatty acids; SCFA

Year:  2021        PMID: 33631190     DOI: 10.1016/j.bcp.2021.114483

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Alterations in the Gut Microbiota and Their Metabolites in Colorectal Cancer: Recent Progress and Future Prospects.

Authors:  Jing Li; Ai-Hua Zhang; Fang-Fang Wu; Xi-Jun Wang
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

Review 2.  Efficacy of probiotics on the modulation of gut microbiota in the treatment of diabetic nephropathy.

Authors:  Nozomi Nagase; Yuka Ikeda; Ai Tsuji; Yasuko Kitagishi; Satoru Matsuda
Journal:  World J Diabetes       Date:  2022-03-15

Review 3.  Gut microbiota modulation: a tool for the management of colorectal cancer.

Authors:  Yan Wang; Hui Li
Journal:  J Transl Med       Date:  2022-04-21       Impact factor: 8.440

4.  Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling.

Authors:  Jiaxing Tan; Lingqiu Dong; Zheng Jiang; Li Tan; Xinyao Luo; Gaiqin Pei; Aiya Qin; Zhengxia Zhong; Xiang Liu; Yi Tang; Wei Qin
Journal:  J Transl Med       Date:  2022-08-29       Impact factor: 8.440

Review 5.  Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes.

Authors:  Angelo Maria Patti; Rosaria Vincenza Giglio; Nikolaos Papanas; Dragos Serban; Anca Pantea Stoian; Kalliopi Pafili; Khalid Al Rasadi; Kanya Rajagopalan; Ali A Rizvi; Marcello Ciaccio; Manfredi Rizzo
Journal:  Medicina (Kaunas)       Date:  2022-01-11       Impact factor: 2.430

6.  GPR43 regulation of mitochondrial damage to alleviate inflammatory reaction in sepsis.

Authors:  Weiwei Zhang; Wusan Wang; Maodi Xu; Haitang Xie; Zhichen Pu
Journal:  Aging (Albany NY)       Date:  2021-09-28       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.